Literature DB >> 15615543

Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5.

Jon Valgeirsson1, Elsebet O Nielsen, Dan Peters, Claus Mathiesen, Anders S Kristensen, Ulf Madsen.   

Abstract

2-Arylureidobenzoic acids (AUBAs) have recently been presented as the first series of selective noncompetitive GluR5 antagonists. In this paper we have modified the acidic moiety of the AUBAs by introducing different acidic and neutral groups, and similarly, we have replaced the urea linker of the AUBAs with other structurally related linkers. Replacing the acid with neutral substituents led to inactive compounds in all instances, showing that an acidic moiety is necessary for activity. Replacing the carboxylic moiety in 2a with a sulfonic acid (5c) or a tetrazole ring (5d) improved the potency at GluR5 receptors (compounds 5c and 5d showed IC(50) values of 1.5 and 2.0 muM, respectively, compared to compound 2a with IC(50) = 4.8 muM). Compound 5c did not show improved in vivo activity in the ATPA rigidity test compared to 2a, whereas compound 5d was 4 times more potent than 2a. All compounds wherein the urea linker had been replaced showed lower or no activity. The results described extend the knowledge of structure-activity relationships for the AUBAs, and compound 5d may prove to be a good candidate for studying GluR5 receptors in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615543     DOI: 10.1021/jm030638w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

Review 1.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  In vitro inhibition of translation initiation by N,N'-diarylureas--potential anti-cancer agents.

Authors:  Séverine Denoyelle; Ting Chen; Limo Chen; Yibo Wang; Edvin Klosi; José A Halperin; Bertal H Aktas; Michael Chorev
Journal:  Bioorg Med Chem Lett       Date:  2011-11-16       Impact factor: 2.823

3.  An Aminative Rearrangement of O-(Arenesulfonyl)hydroxylamines: Facile Access to ortho-Sulfonyl Anilines.

Authors:  Charlotte Morrill; James E Gillespie; Robert J Phipps
Journal:  Angew Chem Int Ed Engl       Date:  2022-07-07       Impact factor: 16.823

Review 4.  Kainate receptor signaling in pain pathways.

Authors:  Sonia K Bhangoo; Geoffrey T Swanson
Journal:  Mol Pharmacol       Date:  2012-10-24       Impact factor: 4.436

5.  Novel analogs and stereoisomers of the marine toxin neodysiherbaine with specificity for kainate receptors.

Authors:  L Leanne Lash; James M Sanders; Nobuyuki Akiyama; Muneo Shoji; Pekka Postila; Olli T Pentikäinen; Makoto Sasaki; Ryuichi Sakai; Geoffrey T Swanson
Journal:  J Pharmacol Exp Ther       Date:  2007-11-21       Impact factor: 4.030

6.  Exploring kainate receptor pharmacology using molecular dynamics simulations.

Authors:  Pekka A Postila; Geoffrey T Swanson; Olli T Pentikäinen
Journal:  Neuropharmacology       Date:  2009-09-06       Impact factor: 5.250

Review 7.  Therapeutic potential of kainate receptors.

Authors:  Carlos Matute
Journal:  CNS Neurosci Ther       Date:  2010-12-06       Impact factor: 5.243

8.  Synthesis and molecular docking of novel non-competitive antagonists of GluK2 receptor.

Authors:  Agnieszka A Kaczor; Tomasz Wróbel; Christiane Kronbach; Klaus Unverferth; Tomasz Stachal; Dariusz Matosiuk
Journal:  Med Chem Res       Date:  2014-07-24       Impact factor: 1.965

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.